A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer
Stopped early · Phase 1
Conditions studied: Advanced Solid Tumor, Ovarian Cancer, Ovarian Clear Cell Carcinoma, Ovarian Clear Cell Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Endometrioid Tumor, ARID1A Gene Mutation
In brief
The purpose of the dose escalation phase is to evaluate the safety profile of escalating doses and dose schedules of NXP800. In the expansion phase the preliminary efficacy in subjects with ARID1a mutated ovarian clear cell and ovarian endometrioid cancers will be estimated.
Key facts
- Study ID
- NCT05226507
- Run by
- Nuvectis Pharma, Inc.
- People needed
- 45
- Starts
- 2021-12-31
- Expected to finish
- 2025-01-01
- Last updated by the study team
- 2026-08-06
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Honor Health — Phoenix, Arizona, United States
- UC San Diego Health - Moores Cancer Center — La Jolla, California, United States
- University of Colorado Cancer Center — Aurora, Colorado, United States
- Yale Gynecologic Oncology — New Haven, Connecticut, United States
- Florida Cancer Specialists South — Fort Myers, Florida, United States
- Mount Sinai Comprehensive Cancer Center — Miami Beach, Florida, United States
- Florida Cancer Specialists Research North — St. Petersburg, Florida, United States
- Florida Cancer Specialists Research East — West Palm Beach, Florida, United States
- University of Iowa — Iowa City, Iowa, United States
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey, United States
- Women's Cancer Care Associates — Albany, New York, United States
- The Ohio State University Comprehensive Cancer Center — Columbus, Ohio, United States
- OU Health Stephenson Cancer Center — Oklahoma City, Oklahoma, United States
- Oklahoma Cancer Specialists and Research Institute — Tulsa, Oklahoma, United States
- Oncology Associates of Oregon — Eugene, Oregon, United States
- Sidney Kimmel Cancer Center, Asplundh Cancer Pavilion — Willow Grove, Pennsylvania, United States
- Texas Oncology — Fort Worth, Texas, United States
- The University of Texas MD Anderson Cancer Center — Houston, Texas, United States
- University of Virginia Health System — Charlottesville, Virginia, United States
- Royal Marsden Hospital — Sutton, Sutton Surrey, United Kingdom
- Addenbrookes Hospital — Cambridge, United Kingdom
- The Beatson West of Scotland Cancer Centre — Glasgow, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.